Melinda L. Burgess

Brisbane, QLD, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Checkpoint inhibitors, obinutuzumab plus PET-adapted ultra-low dose nodal radiotherapy yield high efficacy in treatment-naïve follicular lymphoma: Results from the phase II 'FLUORO' study.

Checkpoint inhibitors, obinutuzumab plus PET-adapted ultra-low dose nodal radiotherapy yield high efficacy in treatment-naïve follicular lymphoma: Results from the phase II 'FLUORO' study.

Journal: British journal of haematology

Published: February 16, 2026

Same-Slide Spatial Multiomics Integration with IN-DEPTH Reveals Tumor Virus-Linked Spatial Reorganization of the Tumor Microenvironment.

Same-Slide Spatial Multiomics Integration with IN-DEPTH Reveals Tumor Virus-Linked Spatial Reorganization of the Tumor Microenvironment.

Journal: Cancer discovery

Published: May 05, 2025

PASTA: versatile tyramide-oligonucleotide amplification for multimodal spatial biology.

PASTA: versatile tyramide-oligonucleotide amplification for multimodal spatial biology.

Journal: Nature methods

Published: April 02, 2025

T-cell dysregulation informs radiotherapy-immunotherapy response in B-cell lymphoma: results from a phase 1 trial.

T-cell dysregulation informs radiotherapy-immunotherapy response in B-cell lymphoma: results from a phase 1 trial.

Journal: Blood advances

Published: March 14, 2025

Nivolumab and rituximab in treatment-naïve follicular lymphoma: the phase 2 1st FLOR study.

Nivolumab and rituximab in treatment-naïve follicular lymphoma: the phase 2 1st FLOR study.

Journal: Blood advances

Published: November 27, 2024

Intra-tumoral and peripheral blood TIGIT and PD-1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphoma.

Intra-tumoral and peripheral blood TIGIT and PD-1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphoma.

Journal: American journal of hematology

Published: June 10, 2024

Systemic diffuse large B-cell lymphoma involving the central nervous system has high rates of defective antigen presentation and immune surveillance.

Systemic diffuse large B-cell lymphoma involving the central nervous system has high rates of defective antigen presentation and immune surveillance.

Journal: Haematologica

Published: November 01, 2023

Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia.

Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: March 20, 2023

Immune priming with avelumab and rituximab prior to R-CHOP in diffuse large B-cell lymphoma: the phase II AvR-CHOP study.

Immune priming with avelumab and rituximab prior to R-CHOP in diffuse large B-cell lymphoma: the phase II AvR-CHOP study.

Journal: Leukemia

Published: November 07, 2022

Resolution of Melanoma to Programmed Death-1 Blockade but Simultaneous Rapid Progression of Concomitant Chronic Lymphocytic Leukemia.

Resolution of Melanoma to Programmed Death-1 Blockade but Simultaneous Rapid Progression of Concomitant Chronic Lymphocytic Leukemia.

Journal: Acta haematologica

Published: June 24, 2022

Correction: HDAC7 is an actionable driver of therapeutic antibody resistance by macrophages from CLL patients.

Correction: HDAC7 is an actionable driver of therapeutic antibody resistance by macrophages from CLL patients.

Journal: Oncogene

Published: December 23, 2020

SIRPα Suppresses Response to Therapeutic Antibodies by Nurse Like Cells From Chronic Lymphocytic Leukemia Patients.

SIRPα Suppresses Response to Therapeutic Antibodies by Nurse Like Cells From Chronic Lymphocytic Leukemia Patients.

Journal: Frontiers in immunology

Published: September 26, 2020

Showing 1-12 of 24

Last Updated: 09/26/2026